首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1566127

藥物基因體學市場規模、佔有率、成長分析，按產品/服務、按技術、按疾病領域、按應用、按地區 - 行業預測，2024-2031

Pharmacogenomics Market Size, Share, Growth Analysis, By Product & Service, By Technology, By Disease Area, By Application, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年藥物基因體學市場規模為61.5億美元，從2023年的66.7億美元成長到2031年的127.8億美元，複合年成長率預計為8.47%。

受基因組研究進步、個人化醫療興起以及精準醫療進步的影響，全球市場情勢正在經歷強勁成長和轉型。人們對個人化治療選擇的認知不斷提高，加上基因組測試擴大融入臨床通訊協定，正在推動市場擴張，尤其是在慢性病變得更加普遍的情況下。此外，基因組資料和電子健康記錄的融合，以及標靶治療的出現，正在顯著增加市場活力。製藥公司、研究機構和監管機構之間的合作也大大推進了藥物基因組學研究。然而，市場面臨挑戰，包括基因檢測的高成本、限制性的報銷政策以及迫切需要廣泛的研發工作。解決這些障礙並最大限度地在臨床實踐中使用藥物基因體學對於市場的持續成功至關重要。值得注意的是，美國藥物基因體學領域預計在未來幾年將保持持續的複合年成長率，顯示該創新領域未來發展的巨大潛力和投資機會。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN
Danaher Corporation
Laboratory Corporation of America Holdings
Eurofins Scientific
Charles River Laboratories
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Becton, Dickinson and Company
Revvity
IQVIA, Inc.
Mesa Labs, Inc.
Medpace, Inc.
MGI Tech Co., Ltd.
PacBio
Takara Bio Inc.
New England Biolabs
BGI
Novogene Co., Ltd.
Sophia Genetics
Fios Genomics
Personalis, Inc.
NeoGenomics Laboratories
BioAI Health Inc.
Macrogen, Inc.

簡介目錄

Product Code: SQMIG35G2248

Pharmacogenomics Market size was valued at USD 6.15 billion in 2022 and is poised to grow from USD 6.67 billion in 2023 to USD 12.78 billion by 2031, growing at a CAGR of 8.47% in the forecast period (2024-2031).

The global pharmacogenomics market is witnessing robust growth and a transformative landscape, largely influenced by breakthroughs in genomic research, the rise of personalized medicine, and the advancement of precision healthcare. A surge in awareness regarding personalized treatment options, coupled with an increasing integration of genomic testing into clinical protocols, is propelling market expansion, especially as chronic diseases become more prevalent. Furthermore, the amalgamation of genomic data with electronic health records, alongside the emergence of targeted therapies, is significantly enhancing market dynamics. Collaborative efforts among pharmaceutical firms, research institutions, and regulatory agencies are also driving considerable progress in pharmacogenomic research. Nonetheless, the market faces challenges, including the high costs associated with genetic testing, restrictive reimbursement policies, and a pressing necessity for extensive R&D efforts. Addressing these barriers and maximally utilizing pharmacogenomics in clinical settings will be crucial for the ongoing success of the market. In particular, the U.S. pharmacogenomics sector is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast year, indicating strong potential for future development and investment opportunities within this innovative field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacogenomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacogenomics Market Segmental Analysis

Global Pharmacogenomics Market is segmented by Product & Service, Technology, Disease Area, Application, End User and region. Based on Product & service, the market is segmented into Kits & Reagents (Sequencing Kits and Reagents, PCR Kits and Reagents, Microarray Kits and Reagents, Other Kits and Reagents), Service. Based on Technology, the market is segmented into Sequencing, PCR, Microarray, and Other Technologies. Based on Disease Area, the market is segmented into Cancer, Cardiovascular, Neurological Diseases, Other Disease Areas. Based on Application, the market is segmented into Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development. Based on End User, the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Pharmacogenomics Market

The rising demand for personalized medicine significantly propels the global pharmacogenomics market, as healthcare stakeholders increasingly recognize the importance of tailoring drug therapies to individual genetic profiles. By leveraging pharmacogenomic insights, clinicians can optimize medication selection and dosages, enhancing efficacy and minimizing adverse effects, thereby leading to safer treatment regimens. This shift towards precision medicine not only improves patient health outcomes but also fosters healthcare efficiency and cost-effectiveness. As more healthcare systems integrate pharmacogenomic testing into routine practices, the market is poised for substantial growth, reflecting a broader trend towards individualized healthcare solutions that cater to each patient's unique genetic makeup.

Restraints in the Pharmacogenomics Market

The global pharmacogenomics market faces significant restraint due to the high costs associated with genetic testing and genomic analysis. These advanced tests necessitate sophisticated laboratory infrastructure and specialized expertise, resulting in expensive procedures that can limit accessibility for patients, particularly in developing regions where healthcare resources are constrained. Moreover, the complex nature of interpreting and integrating genetic data into clinical workflows demands additional specialized training and resources. These financial and technical challenges create substantial barriers to the widespread adoption of pharmacogenomic services, ultimately affecting the market's growth potential and the realization of personalized medicine benefits across diverse populations.

Market Trends of the Pharmacogenomics Market

A prominent trend in the global pharmacogenomics market is the widespread integration of personalized medicine, which tailors drug therapies to align with an individual's unique genetic profile. This paradigm shift, fueled by advancements in genomic research and increased accessibility to genetic testing technologies, empowers healthcare providers to optimize treatment efficacy and mitigate adverse drug reactions. As the healthcare industry increasingly recognizes the importance of genetic insights in medication management, the implementation of pharmacogenomics in clinical settings is anticipated to accelerate, heralding a new era of targeted therapies. This evolution not only enhances patient outcomes but also signifies robust growth potential for the pharmacogenomics market in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Value Chain Analysis
Supply Chain Analysis
Regulatory Landscape
Pricing Analysis
Patent Analysis
Customer & Buying Criteria Analysis

Pharmacogenomics Market, By Product & Service

Market Overview
Kits & Reagents
- Sequencing Kits & Reagents
- PCR Kits & Reagents
- Microarray Kits & Reagents
- Other Kits & Reagents
Services

Pharmacogenomics Market, By Technology

Market Overview
Sequencing
PCR
Microarray
Other Technologies

Pharmacogenomics Market, By Application

Market Overview
Personalized Medicine
Clinical Research
Drug Discovery & Preclinical Development

Pharmacogenomics Market, By Disease Area

Market Overview
Cancer
Cardiovascular Disease
Neurological Disorders
Other Disease Areas

Pharmacogenomics Market, By End User

Market Overview
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations

Pharmacogenomics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revvity
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesa Labs, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MGI Tech Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PacBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novogene Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sophia Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fios Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAI Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrogen, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments